Omeros Corporation (OMER)
NASDAQ · Manufacturing · Pharmaceutical preparations
$19.92−$0.2085 (−1.04%) on the dayAs of the close; data may be delayed.
OMER price, last 12 months
Key stats
- Previous close
- $20.13
- Open
- $20.13
- Day range
- $19.66 – $20.61
- 52-week range
- $4.06 – $21.24
- Volume
- 832.7K
- Avg volume (20 days)
- 1.5M
- Market cap
- $1.5B
Performance
1W+11.5%
1M+9.3%
3M+129.8%
6M+93.4%
YTD+16.0%
1Y+374.3%
vs S&P 500, 1Y+357.5 pts
Technicals and fundamentals
About Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.5B